TARO 162.13 Taro Pharm Inds $TARO Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 2:06 PM

TARO 162.13 Taro Pharm Inds $TARO Hit a 52 week high of 166.58 Currently at 162.13 -2.11 -1.28% With a day low of 161.31 and a total volume of 102,700.

TARO Taro Pharm Inds Recent Headline News

Taro Provides Results for September 30, 2014
Business Wire - 2 hrs 29 mins ago
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today provided unaudited financial results for the three months and six months ended September 30, 2014.
TARO: 162.13 (-2.11)

Taro to Announce Second Quarter Results on November 9, 2014
Business Wire - Wed Nov 05, 2:26PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday, November 9, 2014.
TARO: 162.13 (-2.11)

Use The Relative Strength Line To Qualify A Breakout
at Investor's Business Daily - Wed Oct 29, 5:40PM CDT
Stock charts are a collection of facts and tools: price, volume, moving averages. All of them help you understand how a stock and its investors are responding to market input and supply and demand. One very helpful but often lesser-used tool is the...
TARO: 162.13 (-2.11)

Glaucoma Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qn2l4v/glaucoma_market) has announced the addition of the "Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Merck & Co., Inc. - Alcon, Inc. - Taro Pharmaceutical Industries Ltd. - Pharmacia & Upjohn, Inc. - Teva Pharmaceuticals USA, Inc. - Akorn, Inc. - Pfizer Inc. - Alcon Laboratories, Inc. - Bausch & Lomb Incorporated - JHP Pharmaceuticals, LLC - Mobius Therapeutics, LLC - American Regent, Inc. For more information visit http://www.researchandmarkets.com/research/qn...oma_market
AGN: 196.00 (-1.40), TARO: 162.13 (-2.11), AKRX: 36.59 (-1.29), PFE: 29.92 (-0.12), MRK: 59.34 (+0.08)

Taro Provides Results for Quarter Ended June 2014
Business Wire - Thu Aug 07, 5:47PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

today provided unaudited financial results for the three month period ended June 30, 2014.
TARO: 162.13 (-2.11)

Taro to Announce Results for Quarter Ended June 30, 2014
Business Wire - Mon Aug 04, 4:05PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2014 after market close on Thursday, August 7, 2014.
TARO: 162.13 (-2.11)

4 Stocks Spiking on Big Volume
at The Street - Thu Jul 31, 8:03AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
TARO: 162.13 (-2.11), PNRA: 168.29 (+1.00), EPAY: 25.20 (+0.20), EEFT: 54.22 (+0.03)

Israel's Market Appears Unfazed By Rising Conflict
at Investor's Business Daily - Tue Jul 22, 5:07PM CDT
The conflict between Israel and Palestinians caused the U.S. Federal Aviation Administration on Tuesday to temporarily ban American flights to and from Tel Aviv's Ben Gurion International Airport after a rocket landed near the facility. The airport...
PRGO: 155.77 (+3.28), CSTE: 61.58 (+1.77), EIS: 49.37 (-0.42), TARO: 162.13 (-2.11), ISRA: 30.91 (-0.03), TSEM: 10.23 (-0.09), TEVA: 57.70 (-1.02), MLNX: 44.43 (+0.06), CHKP: 74.67 (+0.16)

Taro Annual Report For Fiscal Year Ended March 31, 2014 on Form 20-F Available
Business Wire - Tue Jul 08, 6:42PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO, "Taro"

announced that its Annual Report for fiscal year ended March 31, 2014 on Form 20-F, filed with the Securities and Exchange Commission (the "SEC"

, is available within the Investor Relations section of Taro's website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to Taro Pharmaceuticals U.S.A., Inc., Three Skyline Drive, Hawthorne, NY 10532, attention: William J. Coote or via email to William.Coote@Taro.com.
TARO: 162.13 (-2.11)

NYSE stocks posting largest percentage increases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
BTH: 8.99 (+0.03), NWHM: 14.06 (-0.96), SFE: 19.78 (-0.26), TRR: 7.15 (+0.05), AZZ: 46.62 (-0.37), EGO: 5.64 (+0.39), TARO: 162.13 (-2.11), ELD.TO: 6.38 (+0.38), PKE: 25.88 (-0.29), MTW: 21.13 (+0.16), GNI: 21.62 (+1.07)

Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...
ACT: 245.91 (-4.47), MYGN: 34.89 (+0.11), NVO: 43.69 (-0.10), TARO: 162.13 (-2.11), SLXP: 91.47 (-47.08), ILMN: 186.35 (-3.52), MYL: 53.11 (-0.39)

3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
TARO: 162.13 (-2.11), ABBV: 61.50 (-1.21), FMS: 35.50 (-0.72)

Why I'm Avoiding Taro Pharmaceuticals
Nathaniel Calloway, The Motley Fool - Motley Fool - Fri Jun 13, 4:14PM CDT
Based purely on financial metrics, Taro Pharmaceuticals looks like a great investment. Taro is Israeli generic and branded pharmaceutical maker focused primarily on dermatology and skincare that has been undergoing unprecedented growth in the...
TARO: 162.13 (-2.11)

Taro Announces Results of Its Extraordinary General Meeting of Shareholders
Business Wire - Thu Mar 27, 4:05PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"

announced that the Company held an extraordinary general meeting of shareholders today, March 27, 2014, at 14 Hakitor Street, Haifa Bay 26110, Israel (the "Extraordinary General Meeting"

. IVS Associates, Inc., a leading provider of independent election services, independently tabulated and certified the voting results of the Extraordinary General Meeting.
TARO: 162.13 (-2.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dentsply Sirona Faces Insider Troubles: An Investor Call

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Tech Breakthroughs in Cancer and Space Energy Aired

Science and Technology at the Forefront Saturday nights usually have folks kicking back with some reality shows or maybe cheering on their favorite sports team. But this September 12, savvy viewers have a chance to dive deep into the guts of cutting-edge science and tech on Bloomberg Television. We're talking about 'Advancements with Ted Danson'—where science isn’t...

Hyosung Targets U.S. AI Power Market with Advanced SST

Hyosung's Game-Changing Move in the AI Power Sector Guess what? The AI era's heating up, and it's dragging the power sector along for a wild ride. Hyosung Chairman Hyun-Joon Cho peered into that future and decided it's all-in time for the U.S. power market. With AI and data centers cranking up power demands like never before, those rickety old wires need an upgrade fast....

Regeneron Faces Class Action Over Tumultuous Trial Results

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Automotive ECU Market Aims $160B by 2033

Automotive ECUs Under the Spotlight Picture this: By 2033, the automotive ECU market is expected to balloon to a whopping $160.59 billion. That's some serious cash, and it ain't just pocket change. This $47 billion jump from 2026 isn't just happening by accident—it's got everything to do with high-octane changes in the industry. With a 5.1% CAGR, you best believe it's a...

CDTL's E-Drive and EMB Shape Future of Automation

A Bumpy Ride Towards Future of Commercial Vehicles In the midst of a bustling Hannover, CDTL, that plucky contender in e-drive systems, is making noise at IAA Transportation 2026. Now, if there's one thing I've learned watching this circus we call the auto industry, it's that innovation rarely strolls in with a polite knock. It barges through the door, often leaving a...

Consumer365 Highlights Happy Head's Personalized Hair Solutions

Tailored Hair Loss Solutions by Happy Head Imagine trying to fit a square peg in a round hole. That's what one-size-fits-all approaches often feel like in the world of hair loss treatments. Happy Head, recognized by Consumer365, takes that notion and turns it on its head, offering personalized minoxidil formulations for women. The key word here is personalized. More Than...

Universal Music Wraps €250M Share Buyback Plan

Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...

Cultural Convergence: Ordos Event Captivates Global Visitors

Ordos: Where Cultures Connect Seamlessly Spanning continents and cultures, the recent 'Warm City' event in Ordos, Inner Mongolia, drew international attention like bees to honey. Now, if you're thinking this is just another cultural shindig, think again. François Tchiegue, an ambassador of China-Africa cultural exchanges, described it best when he noted how the morin...

Dr. Liedtka's LIVE Model: Balance Life’s Priorities

Finding Balance in a Chaotic World Forget the market roller coaster for a second. Let's chat about something else that often feels like a roller coaster—life itself. Dr. Karl D. Liedtka's book, "Be Present, LIVE Fully," dives into that hot mess and offers a way to get a grip on your own sanity. This isn't just another self-help book filled with empty platitudes; it's...